Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Chongqing
Clinical trial register · China

Clinical Trials in Chongqing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca107 Janssen Research & Development, LLC39 Merck Sharp & Dohme LLC39 First Affiliated Hospital of Chongqing Medical University34 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University32
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Chongqing

1078 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Phase 3
228
Bengbu, Fuyang, Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou
2025-01-10
Active, closed
Janssen Research & Development, LLC
Phase 3
813
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Guiyang
2025-01-09
Recruiting
The Second Affiliated Hospital of Chongqing Medical University
Phase 4
264
Chongqing
2025-01-09
Active, closed
TJ Biopharma Co., Ltd.
Phase 2
150
Beijing, Binzhou, Chengdu, Chongqing, Ha’erbin, Hefei, Jiangmen, Kunming
2025-01-09
Active, closed
Xing Liu
Not applicable
150
Chongqing
2025-01-02
Recruiting
Qifu Li
Observational
521
Chongqing
2025-01-02
Active, closed
Mingzhao Xiao
Observational
1,000
Chongqing
2025-01-01
Active, closed
Predictive Value of Tumor Vascular Normalization Scoring in HER-2 Positive Breast Cancer
NCT06868758HER2 Positive Breast Carcinoma, Neoadjuvant Therapy
Chongqing General Hospital
Observational
50
Chongqing
2025-01-01
Recruiting
Xu Yan
Not applicable
64
Chongqing
2024-12-31
By invitation
Mingjian Ge
Not applicable
104
Chongqing
2024-12-24
Recruiting
Waterstone Pharmaceutical (Wuhan) Co., LTD.
Phase 3
420
Bengbu, Wuhu, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhanjiang, Huizhou
2024-12-23
Recruiting
Cytokinetics
Phase 3
1,800
Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Nanning, Harbin, Luoyang
2024-12-19
Recruiting
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
NCT06656494Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
DrugsICP-248·Azacitidine
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
266
Hefei, Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Nanchang
2024-12-18
Recruiting
GlaxoSmithKline
Phase 3
520
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai
2024-12-16
Active, closed
Ausper Biopharma Co., Ltd.
Phase 2
105
Chongqing, Fuzhou, Guangzhou, Changzhou, Zhenjiang, Hangzhou
2024-12-13
Recruiting
Xinqiao Hospital of Chongqing
Not applicable
1,846
Wuhu, Chongqing, Jiangmen, Haikou, Huai'an, Wuxi, Jingdezhen, Dalian
2024-12-12
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1
142
Xiamen, Wuhan, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Linyi
2024-12-12
Recruiting
Hutchmed
Phase 3
412
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Changsha
2024-12-12
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2
115
Chongqing
2024-12-10
Active, closed
The Second Affiliated Hospital of Chongqing Medical University
Observational
202
Chongqing
2024-12-09
Recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
130
Shanghai, Chongqing
2024-12-06
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
116
Chongqing, Guangzhou, Shenzhen, Liuzhou, Wuhan, Changsha, Wuxi, Changchun
2024-12-04
Active, closed
Microplastics in Paraneoplastic and Intratumoral for Colorectal Cancer
NCT07063550Colorectal Cancer (MSI-H), Microplastic Exposure
Dong Peng
Observational
100
Chongqing
2024-12-01
Active, closed
First Affiliated Hospital of Chongqing Medical University
Observational
20
Chongqing
2024-12-01
Active, closed
Dong Peng
Observational
20
Chongqing
2024-12-01
Recruiting
A Prospective Cohort Study on the Treatment of Locally Advanced Gastric Cancer
NCT06760858Gastric Cancer, Gastroesophageal Junction Cancer
DrugTislelizumab
Southwest Hospital, China
Observational
122
Chongqing
2024-12-01
Recruiting
Nuvation Bio Inc.
Phase 3
194
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Shijiazhuang, Zhengzhou
2024-11-27
Recruiting
AstraZeneca
Phase 3
1,160
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-11-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
67
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Huizhou, Jiangmen, Liuzhou
2024-11-21
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
204
Fuyang, Lu'an, Maanshan, Beijing, Chongqing, Fuzhou, Lanzhou, Wuwei
2024-11-21
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
182
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Nanning
2024-11-20
Recruiting
Underdilated-stent Technique Improves Post-TIPS Encephalopathy
NCT07349654Liver Cirrhosis, Variceal Bleeding, Cirrhosis, Ascites Hepatic, Hepatic Encephalopathy (HE)
The Second Affiliated Hospital of Chongqing Medical University
Not applicable
72
Chongqing, Qianjiang
2024-11-19
Active, closed
Daiichi Sankyo
Phase 3
700
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Jinan, Nanchang, Nanjing
2024-11-19
Recruiting
AstraZeneca
Phase 3
1,160
Beijing, Changchun, Changde, Changsha, Chengdu, Chongqing, Dalian, Guangzhou
2024-11-18
Active, closed
Clinical Trial of Lyophilized Haemophilus Influenzae Type b Conjugate Vaccine
NCT06621654Haemophilus Influenzae Type B Infection
CanSino Biologics Inc.
Phase 1
160
Chongqing
2024-11-15
Active, closed
Pfizer
Phase 3
636
Beijing, Chongqing, Guangzhou, Jingzhou, Wuhan, Changsha, Suzhou, Wuxi
2024-11-15
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
552
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shaoguan
2024-11-14
Active, closed
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3
482
Bengbu, Hefei, Maanshan, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou
2024-11-14
Active, closed
Biotheus Inc.
Phase 3
404
Binzhou, Changchun, Changsha, Chengdu, Chenzhou, Chongqing, Dalian, Foshan
2024-11-13
Recruiting
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
NCT07433283Tumor, Solid, Lung Cancer, Pancreas Cancer, Thyroid Cancer
Sichuan Enray Pharmaceutical Sciences Company
Phase 1/2
54
Beijing, Hunan, Chongqing, Fuzhou, Haikou, Heilongjiang, Shanghai, Chengdu
2024-11-12
Recruiting
Boehringer Ingelheim
Phase 3
1,590
Beijing, Changchun, Changsha, Changzhou Shi, Chengdu, Chongqing, Foshan, Fuzhou
2024-11-12
Active, closed
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
60
Fuyang, Hefei, Chongqing, Lanzhou, Guangzhou, Nanning, Zhengzhou, Changsha
2024-11-12
Recruiting
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 3
170
Hefei, Beijing, Chongqing, Lanzhou, Nanning, Guangzhou, Shenzhen, Zhujiang
2024-11-11
Recruiting
Third Military Medical University
Not applicable
2,766
Chongqing
2024-11-11
Not yet open
Nanjing First Hospital, Nanjing Medical University
Observational
1,000
Anqing, Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Quanzhou
2024-11-07
Recruiting
Longitudinal Cohort of Thrombosis and Hemostasis Diseases
NCT06727669Immune Thrombocytopenia, Thrombotic Thrombocytopenic Purpura, Hemophilia A, Acquired, Disseminated Intravascular Coagulation
Peking University People's Hospital
Observational
3,000
Beijing, Zhengzhou, Chongqing
2024-11-01
Active, closed
Dong Peng
Observational
200
Chongqing
2024-11-01
Active, closed
Dong Peng
Observational
200
Chongqing
2024-11-01
Recruiting
Digital Early Warning System for Acute Lung Injury in Liver Surgery
NCT07070362Acute Lung Injury(ALI), Liver Cirrhosis, ARDS, Human, MASLD
Beijing Tsinghua Chang Gung Hospital
Observational
3,000
Beijing, Chongqing, Qingdao
2024-11-01
Active, closed
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
432
Beijing, Changchun, Changcun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou
2024-10-30
Active, closed
Pfizer
Phase 3
609
Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Guilin, Wuhan
2024-10-21
Recruiting
BeOne Medicines
Phase 1
153
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan
2024-10-18
Active, closed
GlaxoSmithKline
Phase 2
23
Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Kunming, Shanghai
2024-10-17
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Observational
364
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning
2024-10-16
Recruiting
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2
100
Chongqing
2024-10-15
Recruiting
Boehringer Ingelheim
Phase 3
1,800
Beijing, Changchun, Changsha, Changzhou Shi, Chengdu, Chongqing, Foshan, Fuzhou
2024-10-14
Active, closed
Capital Medical University
Phase 3
1,300
Fuyang, Huainan, Suzhou, Wuhu, Beijing, Chongqing, Zhangzhou, Foshan
2024-10-10
Recruiting
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Not applicable
620
Chongqing
2024-10-10
Recruiting
Bio-Thera Solutions
Phase 3
406
Beijing, Chongqing, Lanzhou, Guangzhou, Shantou, Shenzhen, Nanning, Zunyi
2024-10-09
Active, closed
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
500
Bengbu, Tongling, Wuhu, Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen
2024-10-08
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Hefei, Beijing, Chongqing, Wanzhou, Fuzhou, Guangzhou, Huizhou, Liuzhou
2024-10-07
Recruiting
BeOne Medicines
Phase 1
310
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Jiamusi, Zhengzhou
2024-10-03
Active, closed
First Affiliated Hospital of Chongqing Medical University
Observational
150
Chongqing
2024-10-01
Active, closed
Impact of Environmental Factors and Metabolomics on Colorectal Cancer.
NCT06643429Colorectal Cancer, Metabolic Disease
Dong Peng
Observational
700
Chongqing
2024-10-01
Active, closed
Dong Peng
Observational
200
Chongqing
2024-10-01
Recruiting
Dingqun Bai
Observational
60
Chongqing
2024-10-01
Recruiting
DK Medical Technology (Suzhou) Co., Ltd.
Not applicable
328
Hefei, Beijing, Chongqing, Guanzhou, Huizhou, Shenzhen, Liuzhou, Nanning
2024-09-30
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Zhenjiang, Xi'an, Shanghai
2024-09-26
Recruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
100
Beijing, Chongqing, Guangzhou, Wuhan, Xi’an, Chengdu, Hangzhou, Huzhou
2024-09-21
Recruiting
Dyadic Sport Stacking Program for Mild Dementia and Their Family Caregivers
NCT06597981Dementia, Family Caregivers, Dyadic Intervention, Health Related Quality of Life
The University of Hong Kong
Not applicable
144
Chongqing
2024-09-19
Active, closed
argenx
Phase 3
141
Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Jinan, Nanchang, Shanghai
2024-09-18
Recruiting
Chongqing Claruvis Pharmaceutical Co., Ltd.
Phase 2/3
254
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Kaifeng, Wuhan, Huai'an
2024-09-14
Recruiting
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
NCT06288360Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative, Neoadjuvant Chemoimmunotherapy
DrugsPaclitaxel-albumin·Camrelizumab·Cisplatin
Tongji Hospital
Phase 2
40
Hefei, Beijing, Chongqing, Lanzhou, Nanning, Wuhan, Changsha, Shenyang
2024-09-12
Recruiting
Statin Combined with Amlodipine Treats Primary Aldosteronism
NCT06523465Primary Aldosteronism, Statin, Mineralocorticoid Receptor Antagonist, Hypertension
DrugsAmlodipine besylate·Simvastatin
Third Military Medical University
Phase 4
180
Chongqing
2024-09-10
Active, closed
Takeda
Phase 3
2,099
Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Wuhan, Zhenjiang, Shanghai
2024-09-04
Active, closed
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 3
72
Beijing, Chongqing, Guangzhou, Changsha, Nanjing, Qingdao, Shanghai, Xi’an
2024-09-03
Recruiting
DualityBio Inc.
Phase 1/2
360
Hefei, Beijing, Jilin City, Chongqing, Fuzhou, Nanning, Harbin, Luoyang
2024-09-03
Recruiting
Anesthesia Induction Scheme for Painless Gastrointestinal Endoscopy Patients Based on Nociceptive Stimulation Monitoring
NCT06604156Depth of Anesthesia, Nociception, Painless Gastrointestinal Endoscopy
Min Su
Observational
220
Chongqing
2024-09-01
Recruiting
Association Between Blood Pressure and Risk of PSCI
NCT06730711Stroke, Cognitive Decline, Blood Pressure
First Affiliated Hospital of Chongqing Medical University
Observational
600
Chongqing
2024-09-01
Recruiting
Tang-Du Hospital
Not applicable
96
Wuhan, Nanjing, Shenyang, Xi'an, Chengdu, Ürümqi, Chongqing, Shanghai
2024-09-01
Active, closed
Metabolism Imaging-genomics for Predicting the Surgical Outcomes of Colorectal Cancer
NCT06614660Colorectal Cancer, Imaging, Metabolomics, Prognosis
First Affiliated Hospital of Chongqing Medical University
Observational
800
Chongqing
2024-09-01
Active, closed
The Second Affiliated Hospital of Chongqing Medical University
Observational
624
Chongqing
2024-09-01
Active, closed
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Not applicable
250
Chongqing
2024-09-01
Active, closed
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Beijing, Cangzhou, Changchun, Changzhi, Chengdu, Chongqing, Dongguan, Foshan
2024-08-30
Active, closed
Boehringer Ingelheim
Phase 3
8,371
Anshan, Beijing, Changzhi, Chaoyang, Chengdu, Chifeng, Chongqing, Foshan
2024-08-30
Active, closed
Gilead Sciences
Phase 3
640
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangxi Zhuang Autonomous Region, Guangzhou, Hangzhou
2024-08-28
Active, closed
Amgen
Phase 2
32
Beijing, Chongqing, Fuzhou, Guangzhou, Jiangmen, Harbin, Wuhan, Tianjin
2024-08-27
Recruiting
The Second Affiliated Hospital of Chongqing Medical University
Phase 4
284
Chongqing
2024-08-26
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
DrugsVolrustomig·Adrucil·Paclitaxel·Cisplatin
AstraZeneca
Phase 2
257
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dongguan
2024-08-22
Active, closed
Wei Zhou
Phase 2
32
Chongqing
2024-08-13
Recruiting
AstraZeneca
Phase 3
620
Beijing, Bengbu, Changchun, Changde, Changsha, Chengdu, Chongqing, Fuzhou
2024-08-12
Recruiting
Qifu Li
Observational
97
Chongqing
2024-08-12
Recruiting
Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
NCT06279351Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
DrugsThalidomide·Cetuximab
Xinqiao Hospital of Chongqing
Phase 2
96
Chongqing
2024-08-11
Recruiting
Chengdu Qingshan Likang Pharmaceutical Co., Ltd
Phase 4
400
Hefei, Beijing, Wuhan, Changsha, Chengdu, Chongqing, Ganzhou, Guangdong
2024-08-09
Recruiting
AstraZeneca
Phase 3
1,018
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-08-07
Active, closed
Amgen
Phase 4
102
Beijing, Chongqing, Guangzhou, Harbin, Huaian, Nanjing, Suzhou, Xuzhou
2024-08-06
Active, closed
Merck Sharp & Dohme LLC
Phase 3
3,000
Beijing, Chongqing, Guangzhou, Huizhou, Shenzhen, Jingzhou, Wuhan, Changsha
2024-08-05
Recruiting
Qifu Li
Not applicable
178
Chongqing
2024-08-01
Recruiting
Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease
NCT05387031Crohn Disease, Stricture; Bowel, Intestinal Stricture
DrugUstekinumab
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
239
Beijing, Chongqing, Guangzhou, Huai'an, Suzhou, Yangzhou, Hangzhou
2024-08-01
Recruiting
AstraZeneca
Phase 3
788
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou
2024-08-01
Recruiting
Biomarkers Related to PSCI: An fNIRS Study
NCT06703307Stroke, Cognitive Decline
Dingqun Bai
Observational
60
Chongqing
2024-08-01
Active, closed
Jie Chen
Not applicable
80
Chongqing
2024-08-01
Recruiting
Xintian Pharmaceutical
Phase 4
234
Chongqing, Xiamen, Guangzhou, Shenzhen, Shunde, Wuhan, Nanjing, Xuzhou
2024-07-30
Active, closed
Merck Sharp & Dohme LLC
Phase 3
686
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Zhanjiang, Nanning
2024-07-24
Active, closed
Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
NCT06054113B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
DrugBlinatumomab
Amgen
Phase 2
18
Hefei, Chongqing, Guangzhou, Wuhan, Suzhou, Shanghai, Tianjin
2024-07-23
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
214
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Qingyuan
2024-07-23
Recruiting
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
NCT06427941Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors
DrugsTislelizumab·Bevacizumab
BeOne Medicines
Phase 1/2
630
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Wuhan
2024-07-23
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
102
Fuyang, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Jiangmen
2024-07-22
Active, closed
Vor Biopharma
Phase 3
191
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Zunyi, Wuhan
2024-07-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Bengbu, Hefei, Beijing, Chongqing, Quanzhou, Xiamen, Guangzhou, Shijiazhuang
2024-07-16
Recruiting
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
132
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Jinan, Shanghai
2024-07-12
Active, closed
Efficacy and Safety of Colchicine After PCI
NCT06472908Coronary Heart Disease, Percutaneous Coronary Intervention, Colchicine
DrugColchicine
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3
8,862
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Harbin, Zhengzhou, Enshi
2024-07-09
By invitation
Dong Peng
Observational
150
Chongqing
2024-07-01
Active, closed
AstraZeneca
Phase 3
339
Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Heilongjiang, Jinan
2024-06-29
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR
AstraZeneca
Observational
1,850
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guiyang, Shijiazhuang
2024-06-25
Active, closed
Novo Nordisk A/S
Phase 3
10,000
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Cangzhou, Shijiazhuang, Harbin
2024-06-25
Recruiting
AstraZeneca
Phase 3
240
Beijing, Chongqing, Dongguan, Guangzhou, Hangzhou, Hengyang, Jining, Nanjing
2024-06-20
Active, closed
Celgene
Phase 3
850
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin, Zhengzhou
2024-06-19
Recruiting
AstraZeneca
Phase 3
1,000
Baotou, Beijing, Changchun, Changsha, Chengdu, Chizhou, Chongqing, Dazhou
2024-06-17
Recruiting
the Effect of High Caloric Oral Nutritional Supplements on Growth and Development of Malnourished Children
NCT05911893Malnutrition, Child, Malnourishment, Nutritional Deficiency, Undernutrition
Children's Hospital of Chongqing Medical University
Not applicable
200
Hefei, Beijing, Jilin City, Chongqing, Guangzhou, Guiyang, Changsha, Nanjing
2024-06-17
Not yet open
Institute of Medical Biology, Chinese Academy of Medical Sciences
Phase 4
2,000
Chongqing
2024-06-15
Active, closed
Merck Sharp & Dohme LLC
Phase 3
550
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2024-06-11
Active, closed
Biotheus Inc.
Phase 3
392
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Foshan, Guangzhou
2024-06-11
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-06-10
Active, closed
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
406
Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Dongguan
2024-06-07
Active, closed
Amgen
Phase 3
563
Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou, Guilin, Nanning, Cangzhou
2024-06-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Huizhou
2024-06-05
Recruiting
A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal Arteries
NCT06539689Peripheral Arterial Disease, Stenosis, Dissection
FrontAce Scientific Co., Ltd
Not applicable
240
Beijing, Chongqing, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Nantong, Shanghai
2024-06-04
Not yet open
A Study on Probiotic Formula in Autistic Children
NCT06419530Autism Spectrum Disorder
Third Military Medical University
Not applicable
156
Chongqing
2024-06
Recruiting
[68Ga]Ga-Sa-DABI-4 PET Imaging of Stimulator of Interferon Gene Expression in Cancer Patients
NCT06419361Stimulator of Interferon Gene, Cancer, Positron Emission Tomography
First Affiliated Hospital of Chongqing Medical University
Early Phase 1
30
Chongqing
2024-05-30
Recruiting
InnoCare Pharma Inc.
Phase 3
476
Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian
2024-05-29
Recruiting
Effects of Intraoperative Targeted Temperature Management on Incidence of Postoperative Delirium and Long-term Survival
NCT06256354Cancer Surgery, Intraoperative Hypothermia, Targeted Temperature Management, Postoperative Delirium
Peking University First Hospital
Not applicable
3,992
Chizhou, Hefei, Ma’anshan, Beijing, Chongqing, Shenzhen, Shijiazhuang, Harbin
2024-05-29
Recruiting
First Affiliated Hospital of Chongqing Medical University
Not applicable
32
Chongqing
2024-05-28
Recruiting
The Affiliated Hospital Of Guizhou Medical University
Not applicable
396
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Nanning, Guiyang, Kaili
2024-05-27
Recruiting
Hutchmed
Phase 1
132
Changsha, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Jinan
2024-05-27
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Jiamusi
2024-05-24
Recruiting
A Study of GLB-001 in Patients With Myeloid Malignancies
NCT06378437Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myelodysplastic Syndromes
DrugGLB-001
Hangzhou GluBio Pharmaceutical Co., Ltd.
Phase 1
108
Hefei, Beijing, Chongqing, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Nanchang
2024-05-24
Recruiting
Daiichi Sankyo
Phase 3
540
Beijing, Changchun, Changsha, Chengdu, Chongqing, Haerbin, Hangzhou, Jiangxi
2024-05-21
Recruiting
The Second Affiliated Hospital of Chongqing Medical University
Phase 4
120
Chongqing
2024-05-21
Recruiting
68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease
NCT06387381PSMA, FAP, Positron-Emission Tomography
First Affiliated Hospital of Chongqing Medical University
Early Phase 1
30
Chongqing
2024-05-20
Recruiting
AstraZeneca
Phase 3
440
Beijing, Bengbu, Chengdu, Chongqing, Hohhot, Mianyang, Shanghai, Shantou
2024-05-20
Recruiting
99mTc-QULIC-5-P1 SPECT Imaging in Patients With Prostate Cancer
NCT06419348Prostate Cancer Stage, PSMA, SPECT
First Affiliated Hospital of Chongqing Medical University
Early Phase 1
30
Chongqing
2024-05-20
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2/3
226
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2024-05-15
Recruiting
Dizal Pharmaceuticals
Phase 3
218
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Nanning
2024-05-13
Active, closed
Sanofi
Phase 3
1,541
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan
2024-05-08
Recruiting
Hutchmed
Phase 2/3
502
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Nanning, Guandong
2024-05-08
Recruiting
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 2
45
Chongqing
2024-05-07
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
244
Beijing, Changchun, Changsha, Chaozhou, Chengdu, Chongqing, Guangzhou, Hangzhou
2024-05-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
473
Hefei, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Nanning, Shijiazhuang
2024-05-03
Recruiting
AstraZeneca
Phase 3
582
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2024-04-29
Recruiting
Tasly Pharmaceutical Group Co., Ltd
Phase 3
430
Beijing, Chongqing, Xiamen, Guangzhou, Baoding, Cangzhou, Shijiazhuang, Daqing
2024-04-26
Recruiting
Hutchmed
Phase 3
316
Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Guanzhou
2024-04-26
Recruiting
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
NCT06288373Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy, Neoadjuvant Chemoimmunotherapy
DrugsCamrelizumab·Nab-paclitaxel·Cisplatin
Tongji Hospital
Phase 2/3
440
Hefei, Beijing, Chongqing, Lanzhou, Nanning, Wuhan, Changsha, Shenyang
2024-04-22
Recruiting
Janssen Research & Development, LLC
Phase 3
641
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai
2024-04-18
Active, closed
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
187
Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin
2024-04-17
By invitation
Chongqing University Cancer Hospital
Not applicable
15,000
Chongqing
2024-04-16
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hohhot
2024-04-16
Active, closed
argenx
Phase 3
119
Beijing, Changchun, Chongqing, Fuzhou, Guangxi, Guangzhou, Guiyang, Ningbo
2024-04-16
Recruiting
AstraZeneca
Phase 3
3,850
Baotou, Beijing, Changchun, Changsha, Chengdu, Chifeng, Chongqing, Guangzhou
2024-04-12
Recruiting
AstraZeneca
Phase 3
675
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-04-11
Active, closed
Janssen Research & Development, LLC
Phase 3
272
Beijing, Cheng Du Shi, Chongqing, Guangzhou, Shenyang, Tianjin, Wenzhou, Wuhan
2024-04-09
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
400
Beijing, Chongqing, Fuzhou, Anyang, Zhengzhou, Huai'an, Nanjing, Jinan
2024-03-30
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
584
Baotou, Beijing, Changsha, Changzhou, Chengdu, Chongqing, Guangzhou, Hangzhou
2024-03-29
Active, closed
AstraZeneca
Phase 3
2,554
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dongguan
2024-03-29
Active, closed
Takeda
Phase 2
213
Chongqing, Guangzhou, Changsha, Changzhou, Shenyang, Shanghai, Chengdu, Hangzhou
2024-03-29
Active, closed
Study of JK07 in Patients With Chronic Heart Failure
NCT06369298Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Salubris Biotherapeutics Inc
Phase 2
282
Changsha, Nanjing, Jining, Chengdu, Beijing, Chongqing
2024-03-28
Active, closed
TJ Biopharma Co., Ltd.
Phase 2/3
450
Anyang, Beijing, Bengbu, Binzhou, Changsha, Chongqing, Dongguan, Foshan
2024-03-28
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
522
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Zhanjiang
2024-03-28
Active, closed
Nanjing IASO Biotechnology Co., Ltd.
Phase 3
260
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang
2024-03-27
Recruiting
Physiological Study of High PEEP in Noninvasive Ventilation
NCT07503509Respiratory Failure With Hypoxia
Chongqing Medical University
Not applicable
50
Chongqing
2024-03-26
Recruiting
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2
180
Beijing, Chongqing, Zhengzhou, Nanjing, Shenzhen
2024-03-22
Active, closed
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
NCT06380660Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer
Acerand Therapeutics (Shanghai) Limited
Phase 1/2
298
Chongqing, Fuzhou, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha, Jinan
2024-03-22
Active, closed
NGGT (Suzhou) Biotechnology Co., Ltd.
Phase 1/2
12
Chongqing, Xiamen
2024-03-21
Recruiting
GlaxoSmithKline
Phase 3
864
Chongqing, Baoding, Nanyang, Beijing, Changsha, Changzhou, Chengdu, Dongguan
2024-03-21
Recruiting
First Affiliated Hospital of Chongqing Medical University
Not applicable
40
Chongqing
2024-03-20
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,942
Beijing, Changsha, Chongqing, Ganzhou, Guangdong, Hangzhou, Huzhou, Jinan
2024-03-13
Recruiting
Shanghai Jiao Tong University School of Medicine
Observational
2,242
Chongqing, Xiamen, Wuwei, Qinzhou, Luoyang, Shangqiu, Xuchang, Wuhan
2024-03-11
Recruiting
Army Medical Center of PLA
Phase 2/3
266
Chongqing
2024-03-08
Active, closed
Eli Lilly and Company
Phase 3
17,300
Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chifeng, Chongqing
2024-03-05
Recruiting
Takeda
Phase 2
268
Chongqing, Xiamen, Guangzhou, Huizhou, Wuhan, Changsha, Changzhou, Suzhou
2024-03-05
Active, closed
CanSino Biologics Inc.
Phase 3
840
Chongqing
2024-03-01
Recruiting
Sichuan University
Phase 2
114
Chongqing, Guiyang, Wuhan, Chengdu, Nanchong
2024-03-01
Recruiting
Multicenter Prospective Cohort Study of Twin Maternal-Child Dyads in China
NCT06414655Twin Pregnancy, Antepartum Condition or Complication, Twin to Twin Transfusion as Antepartum Condition, Pre-Term, Pre-Eclampsia
Peking University Third Hospital
Observational
2,000
Hefei, Beijing, Chongqing, Guangzhou, Shenyang, Jinan, Shanghai, Tianjin
2024-03-01
Active, closed
Sanofi
Phase 3
464
Changchun, Chongqing, Guangzhou, Hangzhou, Nanyang, Ningbo, Shanghai, Shenyang
2024-02-29
Recruiting
Daiichi Sankyo
Phase 2/3
860
Xi’an, Beijing, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanning
2024-02-27
Active, closed
AstraZeneca
Phase 2
127
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongyang, Guangzhou, Hangzhou
2024-02-22
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
100
Hefei, Beijing, Hunan, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-02-22
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yangzhou
2024-02-20
Active, closed
AbbVie
Observational
1,200
Beijing, Chongqing, Guangzhou, Nanjing, Shanghai, Chengdu, Jinhua
2024-02-19
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
104
Chongqing, Fuzhou, Guiyang, Harbin, Changsha, Shenyang, Shanghai
2024-02-05
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
150
Chongqing, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Dalian, Shenyang
2024-02-01
Recruiting
Establishment and Evaluation of Prenatal Prevention and Treatment Strategy for NARDS
NCT06188195Acute Respiratory Distress Syndrome, Respiratory Distress Syndrome, Acute
DrugDexamethasone
The Second Affiliated Hospital of Chongqing Medical University
Not applicable
500
Chongqing
2024-02-01
Recruiting
Myasthenia Gravis Registry in China
NCT06241521Myasthenia Gravis
Huashan Hospital
Observational
1,500
Beijing, Chongqing, Guangzhou, Zhengzhou, Changsha, Suzhou, Xuzhou, Nanchang
2024-02-01
Recruiting
The Second Affiliated Hospital of Chongqing Medical University
Not applicable
330
Chongqing
2024-02-01
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
121
Chongqing, Fuzhou, Guangzhou, Liuzhou, Luoyang, Zhengzhou, Wuhan, Changsha
2024-01-29
Recruiting
Tongji Hospital
Observational
250
Wuhan, Beijing, Changchun, Chongqing, Nanjing
2024-01-20
Active, closed
DualityBio Inc.
Phase 3
541
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2024-01-18
Active, closed
AstraZeneca
Observational
367
Beijing, Chongqing, Anhui, Fujian, Guangdong, Guangxi, Guizhou, Hainan
2024-01-15
Recruiting
Beijing Tiantan Hospital
Phase 3
1,380
Beijing, Chongqing, Qianjiang, Guangzhou, Heyuan, Maoming, Meizhou, Yunfu
2024-01-11
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,182
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou
2024-01-11
Recruiting
RemeGen Co., Ltd.
Phase 2
116
Bengbu, Beijing, Chongqing, Nanning, Changsha, Nanchang, Shenyang, Jinan
2024-01-11
Recruiting
Chengdu New Radiomedicine Technology Co. LTD.
Phase 1
58
Zhengzhou, Suzhou, Shanghai, Chongqing, Tianjin
2024-01-09
Not yet open
China National Study of Adrenal Venous Sampling
NCT06192238Hyperaldosteronism
Chinese Academy of Medical Sciences, Fuwai Hospital
Observational
1,500
Beijing, Chongqing, Xiamen, Lanzhou, Foshan, Guangzhou, Shenzhen, Nanning
2024-01-01
Not yet open
ShiCang Yu
Phase 4
68
Chongqing
2024-01-01
Recruiting
Mingzhao Xiao
Observational
1,000
Chongqing
2024-01-01
Recruiting
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Observational
2,000
Chongqing
2024-01-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,310
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Wuhan, Changsha
2023-12-31
Recruiting
Hinova Pharmaceuticals Inc.
Phase 1/2
84
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Guiyang, Zhengzhou
2023-12-26
Active, closed
Bristol-Myers Squibb
Phase 3
190
Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-12-21
Active, closed
AstraZeneca
Observational
409
Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Nanning, Guiyang, Shijiazhuang
2023-12-20
Recruiting
Tavotek Biotherapeutics
Phase 1
50
Chongqing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Jinan
2023-12-20
Not yet open
ShiCang Yu
Not applicable
20
Chongqing
2023-12-20
Recruiting
Shandong First Medical University
Phase 4
1,200
Chongqing, Zhengzhou, Binzhou, Dezhou, Feicheng, Jinan, Liaocheng, Linqing
2023-12-18
Recruiting
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
NCT06014190Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
DrugHS-20089
Hansoh BioMedical R&D Company
Phase 2
460
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang
2023-12-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,314
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Wuhan, Changsha, Nanjing
2023-12-18
Recruiting
A Study of YL202 in Selected Patients With Advanced Solid Tumors
NCT06107686NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors
DrugYL202 should be infused
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shantou, Guilin
2023-12-15
Recruiting
AstraZeneca
Phase 3
1,145
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dongwan, Fuzhou
2023-12-14
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Hefei, Beijing, Chongqing, Guangzhou, Liuzhou, Nanning, Guiyang, Haikou
2023-12-13
Active, closed
Sanofi
Phase 3
1,655
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou
2023-12-13
Recruiting
Eikon Therapeutics
Phase 1/2
156
Guangzhou, Shijiazhuang, Jinan, Hangzhou, Chongqing, Fuzhou, Shanghai
2023-12-11
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
178
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Luoyang
2023-12-08
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
88
Chongqing, Xi'an
2023-12-07
Recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.
Not applicable
290
Beijing, Chongqing, Changsha, Nanjing, Suzhou, Shanghai, Xi’an, Chengdu
2023-12-01
Not yet open
Jing Huang
Not applicable
200
Chongqing
2023-12-01
Active, closed
AstraZeneca
Phase 3
64
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Ha’erbin, Jinan
2023-12-01
Recruiting
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
NCT06799637Advanced Solid Tumors, Pancreatic Carcinoma, Ovarian Cancer, Cervical Cancers
DrugXNW28012
Evopoint Biosciences Inc.
Phase 1/2
350
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Guiyang, Baoding, Harbin
2023-12-01
Active, closed
Chronic Kidney Disease Registry Platform Study
NCT06117852Chronic Kidney Diseases
AstraZeneca
Observational
5,000
Baotou, Beijing, Changsha, Changzhou, Chengdu, Chongqing, Dongguan, Guangzhou
2023-11-28
Recruiting
AstraZeneca
Phase 3
625
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2023-11-23
Active, closed
AstraZeneca
Phase 3
1,898
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Guilin
2023-11-21
Recruiting
Amgen
Phase 3
750
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2023-11-16
Active, closed
AbbVie
Phase 3
289
Chongqing, Xiamen, Guangzhou, Wuhan, Changsha, Changzhou, Nanjing, Wuxi
2023-11-15
Not yet open
Akeso
Phase 3
642
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Zhangzhou, Lanzhou
2023-11-14
Recruiting
Xueqin Yang
Observational
44
Chongqing
2023-11-13
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2023-11-12
Active, closed
BeOne Medicines
Phase 3
652
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Jieyang, Nanning, Nanyang
2023-11-11
Active, closed
First Affiliated Hospital of Chongqing Medical University
Observational
120
Chongqing
2023-11-11
Active, closed
AstraZeneca
Phase 3
1,835
Baotou, Beijing, Changsha, Chengdu, Chongqing, Deyang, Foshan, Guangzhou
2023-11-07
Recruiting
Janssen Research & Development, LLC
Phase 1
355
Chongqing, Wenzhou, Xi'an
2023-11-01
Recruiting
Juan Kang
Observational
300
Chongqing
2023-11-01
Active, closed
Novartis Pharmaceuticals
Phase 3
612
Hefei, Chongqing, Guangzhou, Shenzhen, Wuhan, Baotou, Nanjing, Nanchang
2023-10-27
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,109
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Guangzhou, Huizhou
2023-10-25
Active, closed
AstraZeneca
Phase 3
895
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2023-10-24
Active, closed
Bristol-Myers Squibb
Phase 3
402
Hefei, Beijing, Chongqing, Xiamen, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2023-10-24
Recruiting
Hoffmann-La Roche
Phase 3
182
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Shanghai
2023-10-22
Recruiting
AbbVie
Phase 3
1,500
Beijing, Chongqing, Guangzhou, Shenzhen, Wuhan, Nanchang, Changchun, Xi'an
2023-10-11
Recruiting
The Second Affiliated Hospital of Chongqing Medical University
Phase 2
1,200
Chongqing
2023-10-10
Recruiting
The Second Affiliated Hospital of Chongqing Medical University
Phase 2
120
Chongqing
2023-10-10
Recruiting
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (B)
NCT07845058Chronic Hepatitis B, Anti-PD-1 Antibody, Anti-PD-L1 Antibody, Peg-IFNα
DrugPeg-IFNα
The Second Affiliated Hospital of Chongqing Medical University
Phase 2
1,200
Chongqing
2023-10-10
Recruiting
The Second Affiliated Hospital of Chongqing Medical University
Phase 2
120
Chongqing
2023-10-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
14,550
Hefei, Beijing, Chongqing, Foshan, Guangzhou, Huizhou, Jiangmen, Shenzhen
2023-10-09
Recruiting
CARsgen Therapeutics Co., Ltd.
Phase 1
30
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guanzhou, Hangzhou, Shanghai
2023-10-08
Recruiting
AbbVie
Phase 3
90
Chongqing, Suzhou, Xi'an, Shanghai, Hangzhou
2023-10-02
Recruiting
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 2
56
Beijing, Chongqing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Chengdu, Hangzhou
2023-09-28
Recruiting
AstraZeneca
Phase 3
800
Beijing, Changde, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou
2023-09-22
Active, closed
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
990
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Dongguan, Foshan, Guangzhou
2023-09-22
Active, closed
Hoffmann-La Roche
Phase 3
1,130
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangdong Province Guangzhou City, Guangzhou
2023-09-18
Recruiting
RemeGen Co., Ltd.
Phase 1/2
221
Anhui, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2023-09-14
Active, closed
Efficacy and Safety of LX101 for Inherited Retinal Dystrophy Associated With RPE65 Mutations
NCT07054632Inherited Retinal Dystrophy Associated With RPE65 Mutations
Innostellar Biotherapeutics Co.,Ltd
Phase 3
30
Guangzhou, Chongqing, Shanghai, Tianjin
2023-09-13
Recruiting
Perioperative Dexmedetomidine and Long-term Survival After Cancer Surgery
NCT06030804Elderly, Cancer Surgery, Dexmedetomidine, Long-Term Survivors
DrugDexmedetomidine
Peking University First Hospital
Not applicable
4,532
Hefei, Beijing, Chongqing, Fuzhou, Jinjiang, Guangzhou, Shenzhen, Nanning
2023-09-12
Recruiting
Gilead Sciences
Phase 3
402
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei
2023-09-07
Recruiting
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409Ph+ ALL, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
DrugOlverembatinib
Ascentage Pharma Group Inc.
Phase 3
350
Bengbu, Chongqing, Guangdong, Zhengzhou, Wuhan, Suzhou, Shanghai, Chengdu
2023-08-31
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
500
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Nanchang, Shanghai
2023-08-28
Recruiting
Chongqing University Cancer Hospital
Not applicable
188
Chongqing
2023-08-25
Recruiting
DualityBio Inc.
Phase 1/2
862
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Baoding, Harbin
2023-08-17
Recruiting
Beijing Continent Pharmaceutical Co, Ltd.
Phase 3
248
Beijing, Shanghai, Bengbu, Changsha, Chongqing, Guizhou, Hangzhou, Henan
2023-08-12
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
364
Hefei, Beijing, Chongqing, Nanning, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2023-08-11
Recruiting
A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies
NCT05862259Malignant Tumor, Immunotherapy, Artificial Intelligence
Xinqiao Hospital of Chongqing
Observational
120
Chongqing
2023-08-10
Active, closed
Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma
NCT05780372Nasopharyngeal Carcinoma, Radiotherapy; Complications
Sun Yat-sen University
Phase 3
474
Chongqing, Dongguan, Guangzhou, Liuzhou, Nanning, Nanchang, Hangzhou
2023-08-08
Active, closed
Bio-Thera Solutions
Phase 2
162
Baotou, Beijing, Changsha, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou
2023-08-01
Active, closed
GeneCradle Inc
Phase 1/2
33
Beijing, Chengdu, Chongqing, Wuhan
2023-08-01
Recruiting
Xinqiao Hospital of Chongqing
Phase 1/2
40
Chongqing
2023-08-01
Recruiting
First Affiliated Hospital of Chongqing Medical University
Observational
500
Chongqing
2023-08-01
Recruiting
GlaxoSmithKline
Phase 3
892
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin
2023-08-01
Recruiting
Xinqiao Hospital of Chongqing
Not applicable
40
Chongqing
2023-08-01
Recruiting
Association of HsCAR with MAFLD and Liver Fibrosis: a Cross-sectional Study
NCT05974904Metabolic Dysfunction-associated Fatty Liver Disease, Hepatic Steatosis, Liver Fibrosis
Chongqing Medical University
Observational
7,000
Chongqing
2023-07-18
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
1,000
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Zhenjiang, Nanchang
2023-07-11
Active, closed
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2
80
Baotou, Beijing, Changsha, Chengdu, Chongqing, Fuyang, Guangzhou, Hengyang
2023-07-06
Recruiting
Children's Hospital of Chongqing Medical University
Observational
2
Chongqing
2023-07-04
Active, closed
Abbisko Therapeutics Co, Ltd
Phase 1
169
Chongqing, Luoyang, Zhengzhou, Wuhan, Changsha, Hohhot, Nanchang, Changchun
2023-06-26
Active, closed
Bristol-Myers Squibb
Phase 3
1,230
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Zhengzhou, Changsha, Nanjing
2023-06-22
Recruiting
Fudan University
Phase 3
764
Beijing, Chongqing, Fuzhou, Guangzhou, Guangdong, Nantong, Yangzhou, Shenyang
2023-06-20
Recruiting
Hoffmann-La Roche
Phase 3
420
Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang
2023-06-07
Active, closed
Eli Lilly and Company
Phase 3
3,127
Hefei, Beijing, Chongqing, Shenzhen, Haikou, Harbin, Luoyang Shi, Zhengzhou
2023-06-05
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin
AstraZeneca
Phase 1/2
622
Chengdu, Chongqing, Guangzhou, Jinan, Xi'an, Zhengzhou
2023-06-05
Recruiting
Sound Biopharmaceuticals Ltd.
Phase 1
44
Beijing, Chongqing, Chengdu
2023-06-05
Active, closed
Biotheus Inc.
Phase 2
50
Beijing, Changchun, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Jinan
2023-06-01
Recruiting
TCRCure Biopharma Ltd.
Phase 1
18
Chongqing
2023-06-01
Recruiting
Fudan University
Phase 3
766
Beijing, Chongqing, Fuzhou, Guangzhou, Guangdong, Nantong, Yangzhou, Shenyang
2023-06-01
Active, closed
Amgen
Phase 3
509
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Jiangmen, Shijiazhuang, Harbin
2023-05-31
By invitation
Abbisko Therapeutics Co, Ltd
Phase 2
64
Beijing, Chongqing, Fuzhou, Guangzhou, Zhujiang, Wuhan, Hangzhou, Suzhou
2023-05-30
Active, closed
Biotheus Inc.
Phase 2
31
Chongqing, Fuzhou, Harbin, Zhengzhou, Jingzhou, Wuhan, Changsha, Yongzhou
2023-05-17
Recruiting
LISH Trial for the Hepatic Flexure and Proximal Transverse Colon Cancer
NCT05923255Hepatic Flexure Colon Cancer, Proximal Transverse Colon Cancer
Zhejiang University
Not applicable
568
Bengbu, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Wuhan, Changsha
2023-05-14
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
480
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning
2023-05-10
Active, closed
Gilead Sciences
Phase 3
654
Anhui, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fujian, Fuzhou
2023-05-08
Active, closed
AstraZeneca
Phase 3
37
Beijing, Chongqing, Yangzhou, Zhengzhou
2023-05-08
Active, closed
First Affiliated Hospital of Chongqing Medical University
Not applicable
60
Chongqing
2023-05-01
Not yet open
Suzhou Puhe Pharmaceutical Technology Co., LTD
Phase 3
350
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou
2023-05-01
Recruiting
Juan Kang
Observational
800
Chongqing
2023-05-01
Not yet open
Chongqing University Cancer Hospital
Phase 2
36
Chongqing
2023-05-01
Active, closed
RemeGen Co., Ltd.
Phase 3
318
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou
2023-04-28
Recruiting
Yuehui Yin
Observational
480
Chongqing
2023-04-27
Active, closed
AstraZeneca
Phase 2
294
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Harbin, Nanning, Shanghai
2023-04-24
Recruiting
shifeng Lou
Not applicable
160
Chongqing
2023-04-20
Active, closed
Klus Pharma Inc.
Phase 2
356
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-04-19
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
154
Chongqing, Harbin
2023-04-13
Active, closed
Janssen Research & Development, LLC
Phase 3
20,284
Beijing, Cangzhou, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Daqing
2023-04-11
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 4
2,260
Nanjing, Changzhou, Chongqing, Dalian, Daqing, Dongguan, Fengcheng, Guangzhou
2023-04-08
Active, closed
Lepu Biopharma Co., Ltd.
Phase 2
238
Beijing, Chongqing, Fuzhou, Guangzhou, Maoming, Shantou, Shaoguan, Zhongshan
2023-04-06
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2
368
Beijing, Chongqing
2023-04-04
Recruiting
Nanfang Hospital, Southern Medical University
Phase 4
7,188
Hefei, Huainan, Suzhou, Beijing, Chongqing, Foshan, Guangzhou, Zhongshan
2023-04-03
Recruiting
Shanghai Hongdian Medical CO., LTD
Not applicable
180
Chongqing, Xiamen, Lanzhou, Guangzhou, Guiyang, Harbin, Zhengzhou, Zhenzhou
2023-03-31
Active, closed
Janssen Research & Development, LLC
Phase 3
614
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2023-03-29
Recruiting
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
220
Beijing, Chongqing, Fuzhou, Nanning, Harbin, Luoyang, Zhengzhou, Changsha
2023-03-27
Active, closed
Janssen Research & Development, LLC
Phase 3
1,135
Beijing, Changchun, Changsha, Chengdu, Chongqing, Deyang, Guangzhou, Hangzhou
2023-03-23
Active, closed
Merck Sharp & Dohme LLC
Phase 3
300
Beijing, Chongqing, Guangzhou, Guiyang, Haikou, Zhengzhou, Wuhan, Changsha
2023-03-16
Recruiting
Teligene US
Phase 2
60
Beijing, Chongqing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2023-03-16
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
191
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Zhengzhou
2023-03-09
Recruiting
OH2 Injection in Melanoma
NCT05868707Melanoma
DrugOH2
Binhui Biopharmaceutical Co., Ltd.
Phase 3
340
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang, Harbin
2023-03-08
Active, closed
Sichuan University
Phase 2
61
Chongqing, Shantou, Wuhan, Shenyang, Jinan, Shanghai, Chengdu, Guiyang
2023-03-07
Not yet open
Peking University First Hospital
Observational
2,000
Hefei, Beijing, Chongqing, Zhengzhou, Shanghai
2023-03
Recruiting
Shanghai AbelZeta Ltd.
Phase 1/2
112
Beijing, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shanghai
2023-02-22
Active, closed
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 2
62
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Meizhou
2023-02-21
Recruiting
First Affiliated Hospital of Chongqing Medical University
Phase 1/2
520
Chongqing
2023-02-20
Recruiting
Chongqing Adrenogenic Autonomic Cortisol Secretion Cohort Study
NCT05743933Diagnosis, Treatment, Adrenogenic Autonomic Cortisol Secretion
Chongqing Medical University
Observational
200
Chongqing
2023-02-17
Active, closed
Takeda
Phase 2
52
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei
2023-02-10
Recruiting
Juventas Cell Therapy Ltd.
Phase 1/2
47
Hefei, Chongqing, Guangzhou, Wuhan, Nanjing, Xuzhou, Nanchang, Tianjin
2023-02-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
614
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2023-02-06
Recruiting
Juan Kang
Observational
300
Chongqing
2023-02-01
Recruiting
Real-world Study Optimizing Nucleotide-analogues
NCT05937178Hepatitis B, Chronic
Huashan Hospital
Observational
20,000
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Nanning, Guiyang
2023-01-31
Active, closed
The Branch-based Intraoperative Stent System in the Treatment of Stanford A Aortic Dissection（BROAD）
NCT05659641Aortic Dissection, Aneurysm, Dissecting, Aneurysm, Vascular Diseases
Permed Biomedical Engineering Co., Ltd
Not applicable
259
Hefei, Chongqing, Fuzhou, Shijiazhuang, Harbin, Wuhan, Nanjing, Nanchang
2023-01-18
Active, closed
Daiichi Sankyo
Phase 3
1,170
Beijing, Beijing Sheng, Cangzhou, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2023-01-11
Recruiting
ShiCang Yu
Not applicable
80
Chongqing
2023-01-09
By invitation
Establishment and Validation of Prediction Model of Simultaneous Chemoradiotherapy for Cervical Cancer Organoids
NCT06786780Cervical Cancer Treated with Pelvic Radiotherapy, Cervical Cancers
Chongqing University Cancer Hospital
Phase 2
50
Chongqing
2023-01-01
Active, closed
Dong Peng
Observational
400
Chongqing
2023-01-01
Active, closed
Three Gorges Hospital of Chongqing University
Observational
150
Chongqing
2023-01-01
Not yet open
Sichuan Provincial People's Hospital
Phase 4
344
Chongqing, Chengdu, Ya'an, Zigong
2023-01
Active, closed
AstraZeneca
Phase 3
1,350
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Jinan, Kunming
2022-12-29
Recruiting
Chongqing University Cancer Hospital
Phase 2
33
Chongqing
2022-12-29
Active, closed
AriBio Co., Ltd.
Phase 3
1,535
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hefei, Heping, Nanchang
2022-12-23
Active, closed
First in Human Study of AZD9592 in Solid Tumors
NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
DrugsAZD9592·Osimertinib·Leucovorin·Adrucil
AstraZeneca
Phase 1
190
Beijing, Chongqing, Guangzhou, Wuhan
2022-12-21
Active, closed
Amgen
Observational
7,000
Beijing, Chongqing, Dongguan, Foshan, Guangzhou, Huizhou, Zhuhai, Guilin
2022-12-19
Active, closed
Novartis Pharmaceuticals
Phase 3
20
Chongqing, Guangzhou, Chengdu, Beijing
2022-12-19
Recruiting
ShiCang Yu
Not applicable
76
Chongqing
2022-12-15
Recruiting
AstraZeneca
Phase 3
3,527
Anyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuyang, Guangzhou
2022-12-13
Active, closed
Dizal Pharmaceuticals
Phase 3
324
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2022-12-13
Active, closed
Janssen Research & Development, LLC
Phase 1/2
57
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Huizhou, Shanghai, Shenyang
2022-12-13
Active, closed
Bellus Health Inc. - a GSK company
Phase 3
997
Kunshan, Leshan, Ürümqi, Beijing, Changsha, Chengdu, Chongqing, Dongguan
2022-12-05
Recruiting
Bio-Thera Solutions
Phase 1
182
Chongqing, Hangzhou
2022-11-30
Active, closed
AstraZeneca
Phase 3
1,174
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2022-11-28
Active, closed
AstraZeneca
Phase 2
47
Beijing, Changsha, Chongqing, Hangzhou, Jinan, Kunming, Nanchang, Ningbo
2022-11-15
Recruiting
Janssen Research & Development, LLC
Phase 2
520
Baoding, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Huizhou
2022-11-11
Recruiting
Hepatitis B Vaccination After Neonatal Surgery
NCT06023056Vaccination Reaction, Hepatitis B Virus Infection, Digestive System Disorders of Fetus and Newborn, Blood Transfusion Complication
Children's Hospital of Chongqing Medical University
Observational
180
Chongqing
2022-11-01
Recruiting
MSD R&D (China) Co., Ltd.
Phase 1/2
203
Chongqing, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Xuzhou, Chengdu
2022-11-01
Active, closed
Hoffmann-La Roche
Phase 3
68
Changsha, Chongqing, Jinan, Shanghai
2022-11-01
Recruiting
Janssen Research & Development, LLC
Phase 3
1,590
Beijing, Changchun, Changsha, Changzhou, Chaoyang District, Chengdu, Chongqing, Fuzhou
2022-10-25
Active, closed
Gilead Sciences
Phase 3
1,021
Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou, Hangzhou, Jiangxi, Jinan
2022-10-12
Active, closed
Eli Lilly and Company
Phase 3
15,374
Beijing, Changchun, Changping, Chengdu, Chongqing, Haikou, Harbin, Hengshui Shi
2022-10-11
Active, closed
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
DrugDonanemab
Eli Lilly and Company
Phase 3
1,500
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou Fujian, Guangzhou, Haidian District
2022-10-10
Active, closed
Dong Peng
Observational
300
Chongqing
2022-10-01
Recruiting
Celgene
Phase 3
810
Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen, Liuzhou, Nanning, Shijiazhuang
2022-09-20
Active, closed
Biogen
Phase 2/3
450
Beijing, Chongqing, Fuzhou, Dongguan, Guangzhou, Shenzhen, Zhongshan, Nanyang
2022-09-13
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Beijing, Chengdu, Chongqing, Ganzhou, Guangzhou, Hangzhou, Hefei, Jinhua
2022-09-13
Recruiting
Guangdong Association of Clinical Trials
Phase 2
180
Beijing, Chongqing, Foshan, Fuzhou, Guangzhou, Guanzhou, Hangzhou, Hefei
2022-09-13
Recruiting
AstraZeneca
Phase 2
454
Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Shanghai, Shenyang, Wuhan
2022-09-06
Recruiting
Mingzhao Xiao
Observational
800
Chongqing
2022-09-01
Recruiting
Teligene US
Phase 2
128
Bengbu, Beijing, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2022-09-01
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
Chongqing, Guangzhou, Zhengzhou, Wuhan, Changchun, Xian, Chengdu, Beijing
2022-08-30
Recruiting
China HeadAche DIsorders RegiStry
NCT05334927Headache Disorders, Primary, Migraine, New Daily Persistent Headache, Medication Overuse Headache
DrugsErenumab·Eptinezumab
Beijing Tiantan Hospital
Observational
10,000
Anqing, Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Shenzhen
2022-08-29
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1
153
Beijing, Chongqing, Nanning, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing
2022-08-23
Active, closed
Sanofi
Phase 2/3
1,856
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanchang
2022-08-22
Active, closed
Bristol-Myers Squibb
Phase 2
34
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Shijiazhuang, Xuzhou, Shenyang
2022-08-19
Active, closed
Janssen Research & Development, LLC
Phase 1
167
Chongqing, Guangzhou, Tianjin, Wuhan
2022-08-18
Recruiting
Allist Pharmaceuticals, Inc.
Phase 1/2
104
Beijing, Chongqing, Xiamen, Shenzhen, Nanning, Shijiazhuang, Harbin, Zhengzhou
2022-08-17
Recruiting
Chongqing University Cancer Hospital
Phase 2
42
Chongqing
2022-08-15
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Beijing, Changchun, Changzhou, Chengdu, Chongqing, Ganzhou, Guangzhou, Hangzhou
2022-08-05
Active, closed
Novartis Pharmaceuticals
Phase 3
506
Hefei, Chongqing, Nanjing, Nanchang, Pingxiang, Changchun, Taiyuan, Chengdu
2022-08-04
Active, closed
AstraZeneca
Phase 3
341
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2022-08-03
Recruiting
China HEalthy Aging and Dementia Study (HEAD)
NCT07912710Alzheimer Disease (AD), Mild Cognitive Impairment (MCI), Dementia, Vascular Dementia (VaD)
Fudan University
Observational
20,000
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan
2022-08-01
Recruiting
Xinqiao Hospital of Chongqing
Observational
20
Chongqing
2022-08-01
Active, closed
AstraZeneca
Phase 4
43
Beijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2022-07-29
Active, closed
Merck Sharp & Dohme LLC
Phase 3
251
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Nanjing, Suzhou, Nanchang
2022-07-27
Active, closed
Janssen Research & Development, LLC
Phase 2
703
Beijing, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Guangzhou, Haikou
2022-07-22
Active, closed
Gilead Sciences
Phase 3
623
Beijing, Changsha, Chengdu, Chongqing, Deyang, Guangzhou, Hangzhou, Harbin
2022-07-20
Active, closed
AstraZeneca
Phase 2
72
Baoding, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou
2022-07-13
Active, closed
AstraZeneca
Phase 1/2
119
Beijing, Bengbu, Changchun, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2022-07-11
Active, closed
Novartis Pharmaceuticals
Phase 4
134
Chongqing, Shijiazhuang, Harbin, Changsha, Nanjing, Suzhou, Changchun, Kunming
2022-07-07
Recruiting
Sun Yat-sen University
Phase 3
766
Chongqing, Guangzhou, Hengyang, Shenyang, Xi'an, Nanchong
2022-07-05
Active, closed
Biotheus Inc.
Phase 1/2
42
Chongqing, Harbin, Nanjing, Nanchang, Jinan, Shanghai, Yibin, Tianjin
2022-07-01
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
432
Bengbu, Wuhu, Beijing, Chongqing, Fuzhou, Lanzhou, Wuwei, Guangzhou
2022-07-01
Active, closed
ArriVent BioPharma, Inc.
Phase 1
160
Hefei, Beijing, Chaoyang, Chongqing, Harbin, Zhengzhou, Wuhan, Xuzhou
2022-06-30
Active, closed
BioDlink Biopharm Co., Ltd.
Phase 3
488
Hefei, Beijing, Jilin City, Chongqing, Fuzhou, Guangzhou, Shantou, Shenzhen
2022-06-28
Recruiting
Chongqing University Cancer Hospital
Not applicable
1,956
Chongqing
2022-06-27
Active, closed
Hoffmann-La Roche
Phase 3
60
Beijing, Changsha, Chongqing, Fuzhou, Hangzhou, Hefei, Linyi, Nanjing
2022-06-14
Recruiting
Antengene Therapeutics Limited
Phase 1
98
Chongqing, Guangzhou
2022-06-07
Active, closed
Pierre Fabre Medicament
Phase 2
63
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2022-06-02
Active, closed
A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
NCT05297890Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
DrugLorlatinib
CStone Pharmaceuticals
Phase 2
70
Guangzhou, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou
2022-05-27
Recruiting
Grit Biotechnology
Phase 1
31
Beijing, Chongqing, Shanghai, Chengdu, Tianjin
2022-05-23
Active, closed
Shanghai Henlius Biotech
Phase 3
511
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Guilin
2022-05-17
Active, closed
AstraZeneca
Phase 3
644
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou
2022-05-16
Recruiting
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
NCT05294731B-cell Malignancy, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
146
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Nanyang
2022-05-06
Recruiting
Third Military Medical University
Observational
350
Chongqing
2022-05-01
Recruiting
Peking Union Medical College Hospital
Observational
20,000
Beijing, Chongqing, Shenzhen, Changsha, Nanjing, Hangzhou
2022-04-29
Active, closed
Shanghai Henlius Biotech
Phase 3
900
Bengbu, Hefei, Lu'an, Ma’anshan, Wuhu, Beijing, Chongqing, Chongqi
2022-04-25
Recruiting
Chongqing University Cancer Hospital
Not applicable
40
Chongqing
2022-04-15
Recruiting
Chongqing University Cancer Hospital
Not applicable
40
Chongqing
2022-04-13
Active, closed
Merck Sharp & Dohme LLC
Phase 3
100
Beijing, Tianjin, Chongqing, Fuzhou, Guangzhou, Shantou, Nanning, Harbin
2022-04-02
Active, closed
AstraZeneca
Phase 3
1,035
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jiaxing
2022-03-25
Recruiting
AbbVie
Phase 3
768
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang
2022-03-25
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,800
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan
2022-03-15
Active, closed
BeOne Medicines
Phase 3
799
Wuhu, Beijing, Chongqing, Fuzhou, Xiamen, Foshan, Guangzhou, Huizhou
2022-03-10
Recruiting
3D Medicines (Sichuan) Co., Ltd.
Phase 2
108
Beijing, Chongqing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Yueyang
2022-03-04
Active, closed
Daiichi Sankyo
Phase 3
740
Nanning, Zhengzhou, Changchun, Chengdu, Beijing, Cangzhou, Changsha, Chongqing
2022-03-04
Active, closed
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
NCT05092412Lung Cancer, Extensive-stage Small-cell Lung Cancer, Durvalumab
DrugDurvalumab
You Lu
Phase 2
30
Chongqing, Zhengzhou, Chengdu
2022-03-02
Recruiting
Xinqiao Hospital of Chongqing
Phase 2
40
Chongqing
2022-03-01
Active, closed
Laekna Limited
Phase 3
256
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Foshan, Guangzhou, Zhongshan
2022-02-18
Active, closed
Merck Sharp & Dohme LLC
Phase 3
8,100
Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Liuzhou, Wuhan, Changsha
2022-02-18
Recruiting
Sanofi
Phase 3
284
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Shanghai, Suzhou, Wuhan
2022-02-15
Active, closed
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
NCT05393427Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors
DrugIza-bren
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
4
Beijing, Chongqing, Chengdu
2022-02-15
Active, closed
PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer
NCT05180734Gastric or Esophagogastric Junction Adenocarcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
878
Bengbu, Chizhou, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Wuwei
2022-02-10
By invitation
UCB Biopharma SRL
Phase 3
300
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming
2022-02-03
Active, closed
Merck Sharp & Dohme LLC
Phase 3
280
Hefei, Beijing, Chongqing, Fulingqu, Fuzhou, Guangzhou, Shantou, Zhanjiang
2022-02-03
Active, closed
Amgen
Phase 1/2
329
Chongqing, Fuzhou, Shanghai
2022-02-01
Recruiting
DualityBio Inc.
Phase 1/2
796
Bengbu, Hefei, Beijing, Hongcun, Chongqing, Xiamen, Lanzhou, Guangzhou
2022-01-31
Recruiting
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
NCT05334823Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia
Chongqing Precision Biotech Co., Ltd
Phase 2
100
Beijing, Chongqing, Shenzhen, Wuhan, Changsha, Nanjing, Suzhou, Nanchang
2022-01-26
Active, closed
Janssen Research & Development, LLC
Phase 3
350
Bengbu, Changsha, Changzhou, Chengdu, Chongqing, Foshan, Fuzhou, Ganzhou
2022-01-19
Recruiting
Genor Biopharma Co., Ltd.
Phase 3
350
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Wenzhou, Xiamen, Foshan
2022-01-14
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
290
Beijing, Chongqing, Guangzhou, Luoyang, Zhengzhou, Wuhan, Nanchang, Changchun
2022-01-14
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
396
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Guanzhou, Nanning
2022-01-06
Recruiting
Clinical Trial of BAO-G Technique in Complex Aortic Aneurysm Endovascular Repair (BAO-G-02)
NCT07141251Thoracoabdominal Aortic Aneurysm, Endovascular Repair, Complex Aortic Aneurysms
Peking Union Medical College Hospital
Not applicable
60
Beijing, Chongqing, Guangzhou, Haikou, Zhengzhou, Jining, Shanghai
2022-01-01
Recruiting
First Affiliated Hospital of Chongqing Medical University
Observational
2,000
Chongqing
2022-01-01
Active, closed
GlaxoSmithKline
Phase 2
366
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming, Shanghai
2021-12-14
Active, closed
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Phase 4
800
Beijing, Chongqing, Lanzhou, Foshan, Guangzhou, Shenzhen, Guiyang, Baoding
2021-12-07
Recruiting
UCB Biopharma SRL
Phase 3
350
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Kunming
2021-12-07
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
69
Chongqing, Guangzhou, Guilin, Jinan, Taizhou
2021-12-07
Recruiting
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
NCT05194982Locally Advanced or Metastatic Solid Tumor
DrugIza-bren
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
570
Chongqing, Guangzhou, Wuhan, Changsha, Shanghai, Taiyuan
2021-11-29
Active, closed
Pediatric Spinal Muscular Atrophy (SMA) China Registry
NCT05042921Muscular Atrophy, Spinal
Biogen
Observational
600
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Nanning
2021-11-18
Active, closed
Janssen Research & Development, LLC
Phase 3
776
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Huizhou
2021-11-17
Active, closed
AstraZeneca
Phase 3
148
Beijing, Changsha, Chongqing, Harbin, Jinan, Nanjing, Shanghai, Shenyang
2021-10-28
Active, closed
AstraZeneca
Phase 3
927
Beijing, Changsha, Chongqing, Guangzhou, Kunming, Nanning, Qingdao, Shanghai
2021-10-25
Recruiting
AstraZeneca
Phase 1/2
460
Beijing, Changsha, Chongqing, Guangzhou, Kunming, Shandong
2021-10-18
Recruiting
Chongqing Medical University
Observational
2,604
Chongqing
2021-10-15
Active, closed
Haihe Biopharma Co., Ltd.
Phase 2
93
Beijing, Chongqing, Guangdong, Haikou, Hainan, Hangzhou, Harbin, Hubei
2021-10-11
Active, closed
PharmaEssentia
Phase 2
49
Beijing, Changsha, Chongqing, Guangzhou, Hefei, Shanghai, Shenzhen, Suzhou
2021-10-08
Active, closed
Loxo Oncology, Inc.
Phase 3
600
Beijing, Changsha, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Hengyang
2021-09-20
Recruiting
BeOne Medicines
Phase 1/2
246
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan
2021-09-16
Active, closed
Nanfang Hospital, Southern Medical University
Observational
1,300
Chongqing, Guangzhou, Hebei, Changsha, Nanjing, Xuzhou, Nanchang, Changchun
2021-09-15
Active, closed
AstraZeneca
Phase 1/2
212
Chengdu, Chongqing
2021-09-14
Recruiting
Zenith Epigenetics
Phase 2
200
Hefei, Chongqing, Xiamen, Zhengzhou, Wuhan, Changsha, Nanjing, Shenyang
2021-09-08
Not yet open
Lepu Medical Technology (Beijing) Co., Ltd.
Not applicable
2,150
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Lanzhou, Foshan, Guangzhou
2021-09
Active, closed
Abbisko Therapeutics Co, Ltd
Phase 1
102
Chongqing, Fuzhou, Ganzhou, Hangzhou, Harbin, Hefei, Mianyang, Nanjing
2021-08-31
Active, closed
Inventiva Pharma
Phase 3
1,000
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Nanning
2021-08-19
By invitation
Viatris Innovation GmbH
Phase 3
25,000
Baotou, Beijing, Cangzhou, Changchun, Changsha, Chaoyang District, Chengdu, Chongqing
2021-08-14
By invitation
Chinese Academy of Medical Sciences
Phase 3
606
Beijing, Changsha, Chendu, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2021-08-01
By invitation
Huashan Hospital
Observational
1,000
Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Wuhan, Nanjing, Suzhou
2021-08-01
Active, closed
Sun Yat-sen University
Phase 3
532
Beijing, Chongqing, Foshan, Guangzhou, Nanning, Guiyang, Wuhan, Changsha
2021-08-01
Active, closed
Sun Yat-sen University
Phase 2
150
Bengbu, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhuhai
2021-07-21
Active, closed
Dizal Pharmaceuticals
Phase 2
104
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Haikou, Hangzhou
2021-07-19
Active, closed
Bristol-Myers Squibb
Phase 3
670
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Dalian, Shanghai, Yiwu
2021-07-13
Active, closed
Janssen Research & Development, LLC
Phase 1
216
Beijing, Chongqing, Guangzhou, Wenzhou
2021-07-13
Active, closed
AstraZeneca
Phase 3
110
Beijing, Chongqing, Guangzhou, Guizhou, Henan, Hubei, Hunan, Jilin City
2021-06-24
Recruiting
Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
NCT04790305Carcinoma Breast, Triple-negative Breast Cancer, Invasive Ductal Carcinoma, Breast
DrugHuaier
Fudan University
Phase 4
1,072
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Harbin, Zhengzhou
2021-06-18
Active, closed
Janssen Research & Development, LLC
Phase 3
1,054
Baoding, Baotou, Beijing, Bengbu, Changchun, Changzhou, Chengdu, Chongqing
2021-06-17
Active, closed
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Phase 4
2,500
Hefei, Beijing, Chongqing, Xianmencun, Dongguan, Guangzhou, Shenzhen, Zhuhai
2021-06-02
Active, closed
D9319C00001- 1L OC Mono Global RCT
NCT04884360Ovarian Cancer
DrugOlaparib
AstraZeneca
Phase 3
366
Baoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang
2021-05-31
Active, closed
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
748
Chizhou, Fuzhou, Hefei, Xuancheng, Beijing, Chongqing, Xiamen, Lanzhou
2021-05-27
Active, closed
AstraZeneca
Phase 3
893
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou
2021-05-10
Recruiting
Sellas Life Sciences Group
Phase 1/2
160
Bengbu, Hefei, Chongqing, Guangzhou, Baoding, Zhengzhou, Suzhou, Nanchang
2021-05-10
Active, closed
Hoffmann-La Roche
Phase 3
1,188
Chengdu, Chongqing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan, Xi'an
2021-05-04
Active, closed
AstraZeneca
Phase 3
1,157
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Guangzhou, Hangzhou
2021-04-26
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
60
Beijing, Chongqing, Guangzhou, Shenzhen, Xian, Chengdu
2021-04-14
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
DrugNemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
490
Hefei, Beijing, Chongqing, Guangzhou, Liuzhou, Nanning, Zhengzhou, Wuhan
2021-04-05
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
687
Chongqing, Nanjin, Guiyang, Shanghai, Tianjin
2021-04-01
Active, closed
Novo Nordisk A/S
Phase 3
1,205
Beijing, Chongqing, Foshan, Guangzhou, Shenzhen, Shijiazhuang, Changsha, Changzhou
2021-04-01
Recruiting
Boston Scientific Corporation
Observational
5,000
Chaoyang, Xicheng, Chongqing, Guangzhou, Qingdao, Huangpu, Yangpu, Taiyuan
2021-03-29
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
496
Shanghai, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang
2021-03-18
Active, closed
Hoffmann-La Roche
Phase 3
746
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Kunming
2021-03-17
Active, closed
Hoffmann-La Roche
Phase 3
342
Anhui, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2021-03-12
Recruiting
Biotheus Inc.
Phase 1/2
380
Baoji, Beijing, Changchun, Changde, Changsha, Changzhou, Chengdu, Chongqing
2021-03-09
Recruiting
Three Gorges Hospital of Chongqing University
Observational
40
Chongqing
2021-03-01
Active, closed
Mirati Therapeutics Inc.
Phase 3
453
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Liuzhou, Harbin, Xinxiang
2021-02-23
Active, closed
AstraZeneca
Phase 3
1,371
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian
2021-01-28
Active, closed
Jilin University
Not applicable
350
Changchun, Beijing, Chongqing, Guangzhou, Shanghai, Shenyang
2021-01-27
Recruiting
Pfizer
Phase 3
2,100
Bengbu, Hefei, Beijing, Chongqing, Lanzhou, Shenzhen, Haikou, Shijiazhuang
2021-01-15
Recruiting
Chongqing University Cancer Hospital
Not applicable
452
Chongqing
2021-01-11
Active, closed
Merck Sharp & Dohme LLC
Phase 3
990
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Harbin, Wuhan
2021-01-10
Recruiting
Surfactant for Neonatal Respiratory Distress Syndrome(NRDS) and Neonatal Acute Respiratory Distress Syndrome(NARDS)
NCT04777760Respiratory Distress Syndrome, Preterm Birth, Acute Respiratory Distress Syndrome, Surfactant Dysfunction
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Observational
400
Chongqing
2021-01-01
Recruiting
Environment, Inflammation and Metabolic Diseases Study
NCT07512609Endocrine Disease, Metabolic Disorders, Hypertension, Diabetes Mellitus
Qifu Li
Observational
8,000
Chongqing
2020-12-25
Recruiting
Juventas Cell Therapy Ltd.
Phase 2
100
Beijing, Chongqing, Guangzhou, Sanhe, Zhengzhou, Wuhan, Xuzhou, Shanghai
2020-12-24
Recruiting
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647Autoimmunity, Inflammation
DrugSecukinumab
Novartis Pharmaceuticals
Phase 4
1,000
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Shantou, Shenzhen, Wuhan
2020-12-22
Active, closed
Pfizer
Phase 3
841
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Nanjing
2020-12-21
Active, closed
AstraZeneca
Phase 3
358
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Kunming, Nanchang
2020-12-16
Active, closed
Merck Sharp & Dohme LLC
Phase 3
672
Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhengzhou, Wuhan, Changsha
2020-12-08
Active, closed
Janssen Research & Development, LLC
Phase 3
518
Beijing, Changchun, Changsha, Changsha Shi, Chengdu, Chongqing, Guangzhou, Hangzhou
2020-12-07
Active, closed
Daiichi Sankyo
Phase 3
1,600
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2020-12-04
Recruiting
Mirati Therapeutics Inc.
Phase 2/3
626
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shenzhen
2020-12-02
Active, closed
AstraZeneca
Phase 1/2
702
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Harbin, Jining
2020-11-12
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
60
Beijing, Chongqing, Xiamen, Zhengzhou, Wuhan, Shanghai, Chengdu
2020-11-10
Active, closed
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
47
Hefei, Beijing, Chongqing, Guangzhou, Changsha, Shanghai, Tianjin, Hangzhou
2020-11-04
Recruiting
Juventas Cell Therapy Ltd.
Phase 2
60
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Jinan, Shanghai, Chengdu
2020-10-26
Active, closed
Gilead Sciences
Phase 2
80
Beijing, Shenyang, Hangzhou, Changchun, Changsha, Chengdu, Chongqing, Guangzhou
2020-10-23
Rows per page Showing 501–1000 of 1078
Previous 1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/chongqing?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,078 of those studies with a site in Chongqing.

How many clinical trials are recruiting in Chongqing?

603 of the 1,078 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 123 have not yet opened recruitment, 338 are active but closed to new participants, and 14 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.